Skip to Content
Merck
All Photos(1)

Documents

GE17-5280-02

nProtein A Sepharose™ 4 Fast Flow

Cytiva 17-5280-02, pack of 200 mL

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

UNSPSC Code:
41106500
NACRES:
NA.56

ligand

native protein A (S. aureus)

packaging

pack of 200 mL

manufacturer/tradename

Cytiva 17-5280-02

storage condition

(20% Ehtanol)

matrix

4% cross-linked agarose

average diameter

90 μm (d50v)

working range

3-9

capacity

>30 mg binding capacity(human IgG/ml)

suitability

suitable for bioprocess medium

storage temp.

2-8°C

General description

nProtein A Sepharose™ 4 Fast Flow is native protein A coupled to Sepharose™ 4 Fast Flow for the purification of monoclonal and polyclonal antibodies at both laboratory and process scale.

nProtein A Sepharose™ 4 Fast Flow is native protein A coupled to the well established Sepharose™ 4 Fast Flow base matrix. The native protein A ligand is produced by fermenting a selected strain of Staphylococcus aureus. The purified protein is coupled to the cross-linked 4% agarose base matrix by the cyanogen bromide technique, giving a highly stable medium with minimal non-specific adsorption. nProtein A Sepharose™ 4 Fast Flow is manufactured without using animal-derived components.

nProtein A Sepharose™ 4 Fast Flow has nearly twice the total IgG binding capacity of Protein A Sepharose™ CL-4B, and is suitable for recovery and purification of monoclonal antibodies from cell culture at both laboratory and process scale. nProtein A Sepharose™ 4 Fast Flow was developed and tested in co-operation with leading manufacturers of purified monoclonal antibody products, and is used in routine commercial production.

As member of the BioProcess media range, nProtein A Sepharose™ 4 Fast Flow meets industrial demands with security of supply and comprehensive technical and regulatory support.

Features and Benefits

  • Replaces Protein A Sepharose™ 4 Fast Flow, the first Cytiva Protein A medium for large-scale purification of antibodies.
  • Used in routine commercial production of monoclonal antibodies
  • Free from animal-derived components.

Analysis Note

To view the Certificate of Analysis for this product, please visit www.cytiva.com.

Legal Information

Sepharose is a trademark of Cytiva

Pictograms

Flame
GHS02

Signal Word

Warning

Hazard Statements

H226

Storage Class Code

3 - Flammable liquids

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Caleigh Mandel-Brehm et al.
Annals of neurology, 92(2), 279-291 (2022-04-26)
Rapid-onset Obesity with Hypothalamic Dysfunction, Hypoventilation and Autonomic Dysregulation (ROHHAD), is a severe pediatric disorder of uncertain etiology resulting in hypothalamic dysfunction and frequent sudden death. Frequent co-occurrence of neuroblastic tumors have fueled suspicion of an autoimmune paraneoplastic neurological syndrome
Monique G P van der Wijst et al.
Science translational medicine, 13(612), eabh2624-eabh2624 (2021-08-26)
Neutralizing autoantibodies against type I interferons (IFNs) have been found in some patients with critical coronavirus disease 2019 (COVID-19), the disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, the prevalence of these antibodies, their longitudinal dynamics across
Sara E Vazquez et al.
eLife, 9 (2020-05-16)
The identification of autoantigens remains a critical challenge for understanding and treating autoimmune diseases. Autoimmune polyendocrine syndrome type 1 (APS1), a rare monogenic form of autoimmunity, presents as widespread autoimmunity with T and B cell responses to multiple organs. Importantly
Paul Bastard et al.
Science immunology, eabp8966-eabp8966 (2022-07-21)
Life-threatening 'breakthrough' cases of critical COVID-19 are attributed to poor or waning antibody response to the SARS-CoV-2 vaccine in individuals already at risk. Pre-existing autoantibodies (auto-Abs) neutralizing type I IFNs underlie at least 15% of critical COVID-19 pneumonia cases in

Articles

Purification Using Protein A-based Chromatography Media

This page shows various purification options for Protein A Sepharose chromatography media and describes typical binding and elution conditions for Protein A Sepharose chromatography media.

Immunoprecipitation Techniques

This page describes immunoprecipitation (immunoaffinity or pull-down techniques).

Column Packing and Preparation for Affinity Chromatography of Antibodies

This page describes efficient column packing and preparation for affinity chromatography of antibodies.

Protocols

Pull-down assays

This page provides information about different pull-down assays for the further isolation of multiprotein complexes to identify their components with products from Cytiva.

Protein A-Based Separation with Cytiva Products

Protein A, coupled to Sepharose, binds IgG via its Fc regions, facilitating affinity chromatography purification.

Protein A-Based Separation with Cytiva Products

Protein A, coupled to Sepharose, binds IgG via its Fc regions, facilitating affinity chromatography purification.

Protein A-Based Separation with Cytiva Products

Protein A, coupled to Sepharose, binds IgG via its Fc regions, facilitating affinity chromatography purification.

See All

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service